Lumos Diagnostics Holdings Ltd (ASX:LDX) has received a significant boost to its development of FebriDx – a test which uses a blood sample to show if a patient has a bacterial infection – with a US government department coming on board to support a study and FDA (Food and Drug Administration) application to the tune of nearly US$3 million. Lumos has received US$2,984,571 in non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA) for an upcoming Clinical Laboratory Improvement Amendments (CLIA)-waiver clinical study and regulatory submission for its FebriDx …